Company intelligence / Profile preview
Thrasos Therapeutics
Montreal, Quebec, Canadathrasos.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
THR‑184 has shown safety and tolerability in two Phase I trials and demonstrated efficacy in animal models. A large Phase II trial was completed for AKI prevention post-cardiac surgery. The compound received FDA Fast Track designation. Preclinical data also support efficacy against kidney injury via anti-apoptotic, anti-inflammatory, and anti-fibrotic mechanisms.
- Therapeutic areas
- NephrologyHematology
- Modalities
- PeptidesSmall molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
GlaxoSmithKline’s SR One venture arm investedBDC Capital Healthcare Venture Fund invested
Beyond the preview
Go deeper on Thrasos Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Thrasos Therapeutics.